



Untreated and Dried Sample Analysis by Solid Probe Assisted Nano Electrospray Ionization Mass Spectrometry

Journal:	<i>Analytical Methods</i>
Manuscript ID:	AY-ART-11-2014-002607.R2
Article Type:	Paper
Date Submitted by the Author:	04-Feb-2015
Complete List of Authors:	Mandal, Mridul Kanti; University of Notre Dame, Department of Chemistry and Biochemistry Saha, Subhrakanti; University of Minnesota, Masonic Cancer Center Yu, Zhan; Shenyang Normal University, Yoshimura, Kentaro; University of Yamanshi, Department of Anatomy and Cell Biology, Interdisciplinary Graduate School of Medicine and Engineering Takeda, Sen; University of Yamanshi, Department of Anatomy and Cell Biology, Interdisciplinary Graduate School of Medicine and Engineering Hiraoka, Kenzo; University of Yamanashi, Clean Energy Research Center

1
2
3 **Untreated and Dried Sample Analysis by Solid Probe Assisted Nano Electrospray**
4
5
6 **Ionization Mass Spectrometry**
7
8
9
10
11
12
13
14

15 Mridul Kanti Mandal,^{*‡a} Subhrakanti Saha,^{§a} Zhan Yu,^{a,b} Kentaro Yoshimura,^c Sen Takeda,^c and
16
17 Kenzo Hiraoka^{*a}
18
19

20
21 ^aClean Energy Research Center, University of Yamanashi, 4-3-11 Takeda, Kofu, Yamanashi,
22
23 400-8511 Japan.
24
25

26 ^bSchool of Chemical and Life Sciences, Shenyang Normal University, Shenyang, 110034, China
27
28

29 ^cDepartment of Anatomy and Cell Biology, Interdisciplinary Graduate, School of Medicine and
30
31 Engineering, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
32
33
34
35
36
37

38 **Current address:**
39
40

41 [‡] Mridul Kanti Mandal
42
43

44
45 Department of Chemistry and Biochemistry
46
47

48 University of Notre Dame, Notre Dame IN 46556USA
49
50

51 Email: mmandal@nd.edu
52
53

54 [§] Subhrakanti Saha
55
56
57

1
2
3 The RNA Institute
4

5
6 Life Science Research Building 2027
7

8
9 State University of New York at Albany
10

11
12 1400 Washington Avenue
13

14
15
16 Albany, NY 12222
17

18
19 **Corresponding author:**
20

21
22 M.K. Mandal, mmandal@nd.edu, Tel: +1-574-631-9027
23

24
25
26 K. Hiraoka, hiraoka@yamanashi.ac.jp; Tel: +81-55-220-8572
27

Abstract:

The present paper describes the application of solid probe assisted nano electrospray ionization mass spectrometry (SPA-nanoESI-MS) for the direct analysis of samples in solid or dried form. The experimental procedure is simple and requires a metallic needle to touch the sample surface followed by inserting the needle to a solvent preloaded nano-capillary. A number of real-world samples in solid or dried form comprising proteins, drugs in tablets, illicit drug in dried urine, lipids in tissues were analyzed to evaluate the applicability of the technique in diverse fields. The technique can produced high quality mass spectra without clogging the capillary tip. Semiquantitative aspect of this technique was evaluated using morphine from dried urine. In addition, biofluids/biomolecules captured on the needle tip and stored for several days at room temperature produced almost similar spectra compared to the fresh samples for cancerous and noncancerous tissues. The high sensitivity, versatile applicability and capability of dried sample analysis extend the scope of SPA-nanoESI to new ventures like bioanalytical and forensic analysis as well as clinical diagnosis.

Introduction:

Mass spectrometry (MS) is one of the most sensitive analytical techniques having wide applicability in complex sample analysis with high specificity.^{1,2} This technique is highly adoptable for both qualitative and quantitative studies in diverse fields.¹⁻³ Gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) are the preferred MS based techniques for forensic and regulatory laboratories where a large number of samples need to be analyzed in rapid and reliable basis.⁴⁻⁷ Both GC-MS and LC-MS require time consuming chromatographic separations and the real-world samples such as urine and biological tissues need to undergo liquid-liquid or solid phase extraction prior to the analysis.⁴⁻⁷

Ambient mass spectrometry based techniques and their applications are favorably increasing since the development of desorption electrospray ionization (DESI) and Direct analysis in real time (DART). These techniques overcome most of the precautions (extraction, pre-concentration, derivatization, etc.) crucial for conventional GC-MS or LC-MS analysis and get exceptional access to analyze the raw biological samples directly or with minimal pre-treatment.⁸⁻¹⁰ DESI is basically a spray based direct desorption and ionization technique¹¹ and DART is a plasma based ionization technique,¹² which have been used for rapid onsite sample screening from complex matrices with sufficient specificity and sensitivity. Chiefly the high tolerance to impurities, matrices and high speed scanning with adequate specificity and sensitivity led the ambient MS techniques particularly useful for rapid and reliable screening of illicit drugs from body fluids¹³⁻¹⁵ and components of biological tissues in dried, frozen and fresh forms.¹⁶ In addition, conventional electrospray ionization (ESI) technique has been used as an auxiliary ionization source, e.g., electrospray-assisted laser desorption/ionization (ELDI),¹⁷ laser ablation with electrospray ionization (LAESI),¹⁸ matrix assisted laser desorption electrospray

1
2
3 ionization (MALDESI)¹⁹ and laser-induced acoustic desorption electrospray ionization
4
5 (LIAD/ESI)²⁰ to analyze untreated and dried sample directly from the surface.
6
7

8 The use of biological tissues as a direct electrospray emitter has also been reported in
9
10 tissue spray,^{21,22} leaf spray,²³ and needle biopsy/direct electrospray from the biopsied tissue.²⁴
11
12 But solvents were applied on the sample surface in all of the above mentioned methods to extract
13
14 the target analytes and produce a stable ESI beam. A simple spot sampling method was
15
16 developed by Van Berkel et al. using a liquid microjunction surface sampling probe/electrospray
17
18 ionization mass spectrometry which has been used for direct biological tissue analysis from the
19
20 dried and frozen surface.^{25,26} Recently, Roach et al. reported a method called nanospray
21
22 desorption electrospray ionization (Nano-DESI) for liquid-extraction surface sampling in mass
23
24 spectrometry using similar approach.²⁷ Additionally, several cost effective techniques such as
25
26 paper spray,²⁸ touch spray,²⁹ wooden-tip ESI,³⁰ Al-foil ESI,³¹ and pipette-tip ESI³²⁻³⁵ were
27
28 reported in recent time for the real world sample analysis.
29
30
31
32
33

34 In 2007 probe electrospray ionization mass spectrometry (PESI-MS) was developed
35
36 using a solid needle.³⁶ Prior to this development, ESI was also performed from a solid metal
37
38 probe by Hong et al.³⁷ The novel feature of electrospray generated from solid needle/probe is that
39
40 it produces the discontinuous sampling namely sequential and exhaustive ionization.³⁸ Therefore,
41
42 PESI-MS can be applied to protein and peptides analysis with high-concentration salts and
43
44 detergents solution.^{39,40} Due to ease in handling, PESI has been applied to cancer diagnosis,⁴¹⁻⁴⁴
45
46 imaging,⁴⁵ plant compound analysis⁴⁶, organometallic compound analysis,⁴⁷ and narcotics
47
48 monitoring from complex biomaterials.⁴⁸ PESI has also been applied to the solvent free green
49
50 chemistry,⁴⁹ and single cell analysis.⁵⁰ For the real time and direct chemical constituents analysis
51
52 from dry and real-world samples, a sheath-flow probe electrospray ionization mass spectrometry
53
54
55
56
57
58
59
60

1
2
3 (SF-PESI-MS) has been developed.^{51,52} A novel ambient ionization method namely Leidenfrost
4
5 phenomenon assisted thermal desorption (LPTD) coupled to dielectric barrier discharge (DBD)
6
7 ionization mass spectrometry has been developed recently and applied for identifying the trace
8
9 level of narcotics and anabolic steroids in urine.^{53,54}
10
11

12
13 For the direct micro-extraction and sampling for mass spectrometry, solid probe assisted
14
15 nano-electrospray ionization (SPA-nanoESI) was also developed.⁵⁵ In SPA-nanoESI, sample was
16
17 extracted using a metallic needle tip by sticking it to the biological tissue and then the needle was
18
19 inserted into the solvent-preloaded nanoESI capillary from solvent loading side and electrospray
20
21 was generated by applying voltage on nanoESI capillary.⁵⁵ Alternatively, a gel loading pipette tip
22
23 was used instead of nanoESI capillary to facilitate the direct and selective analysis and cancer
24
25 diagnosis.³³ In this study SPA-nanoESI was applied for the direct analysis of dried/powder
26
27 narcotics, drug tablets and narcotic screening from dried raw urine. Further, the technique was
28
29 extended to analyze the biomolecules from dried biological tissues.
30
31
32
33
34
35
36
37
38
39

40 *Solvents and Reagents*

41
42 All solvents and reagents used in this study were of analytical grade or higher and were used
43
44 without further purification. Water was purified by a Milli-Q system (Millipore, Bedford, MA).
45
46 High-performance liquid chromatography (HPLC) grade organic solvents were purchased from
47
48 Kanto Chemicals (Tokyo, Japan). All protein standards were obtained from Sigma-Aldrich
49
50 (Tokyo, Japan).
51
52
53
54

55 *Sample Preparation*

1
2
3 The urine samples were prepared by spiking 1 mL of raw urine with 10 μ L of the stock solution
4 of morphine (50 mg/ml). The spiked sample was further diluted directly in raw urine without
5 using any solvent. Kidney tissues were about $10 \times 4 \times 2 \text{ mm}^3$ in size. Cancer tissues from
6 patients diagnosed as clear cell renal cell carcinoma (ccRCC) and their uninvolved kidney tissues
7 were obtained from the Department of Surgery, Faculty of Medicine, University of Yamanashi.
8 All the procedures relating to the handling of human specimens were approved by the Ethical
9 Committee of the Faculty of Medicine, University of Yamanashi. Appropriate precautions
10 should be taken when handling cancerous biomaterials.
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 *Experimental*

26
27
28 The experimental procedure was similar to our previous study (SPA-nanoESI) and is shown
29 schematically in Fig 1. In brief, a 0.3 mm acupuncture needle with submicron tip diameter was
30 touched to the powder sample by dipping in 1-2 mm or stuck into the tablet. The sample amount
31 can be determined by depositing absolute amount of the analytes in solution on the needle tip.
32
33 500 nl sample was loaded by gel loading pipette tip on the needle tip and waited for complete
34 drying. To deposit the sample solution easily a sample piece of chromatography paper ($\sim 2 \times 0.5$
35 $\times 0.18 \text{ mm}^3$) could be stuck to the needle tip. Additionally, after biological tissue sampling, the
36 needle was stored in a glass vial at room temperature for several days for representing as dried
37 real world biomaterials and served for the measurements. After sampling, the needle was
38 inserted into a nanoESI capillary, in which 2 μ L of organic solvent (e.g., acetonitrile, methanol
39 or iosopropanol) was preloaded. The electrospray duration for 2 μ L solution was about 20 min,⁵⁵
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of 5 mm in front of the inlet of a mass spectrometer. High voltage (0.5-1.5 kV) was applied to
4 the metal coated part of the nanoESI capillary for electrospray. Alternatively high voltage can be
5 applied to the needle that produces exactly same mass spectra. The experiments were performed
6 at least three times to ensure the excellent reproducibility.
7
8
9
10
11
12
13
14
15
16

17 **Results and Discussion**

18
19
20 Surface analysis techniques such as infrared (IR)⁵⁶, near-infrared (NIR)^{57,58}, Raman⁵⁹ and
21 fluorescence^{60,61} spectroscopy have normally been applied for the fast screening of unknown
22 tablets in solid forms as sample preparation and separation are not required.⁶² But the sensitivity
23 and reliability of these techniques are much lower compared to the mass spectrometry. In 2006,
24 Leuthold et al. reported the usefulness of drug analysis in emergency departments of hospitals or
25 police department where patients and addicted persons arrive with unknown tablets and powders
26 in their pockets and a rapid analysis of the tablets could save precious time for diagnostics.⁶²
27 Powder narcotics can readily be analyzed using SPA-nanoESI by simply touching the powder or
28 tablets using a needle tip and then inserting the needle to the solvent preloaded nanoESI capillary.
29 Fig. 2 illustrates mass spectrum obtained from opium powder. Opium is the dried latex from
30 the opium poppy (*Papaver somniferum*) seed pod. Several alkaloids including codeine, morphine,
31 thebaine, parpavrine, noscapine, and corydaline are detected from opium powder shown in Fig.2.
32 The alkaloids⁶³ were identified by their exact masses using Exactive Orbitrap mass spectrometer
33 (Thermo Fisher Scientific, Bremen, Germany). Supplementary Fig. 1(a-d) shows the mass
34 spectra of other narcotics such as methamphetamine, cocaine, morphine, and codeine,
35 respectively.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 A standard morphine solution as well as morphine-spiked urine was used to calculate the
4 precision, linear ranges, correlation coefficient (R^2), and recovery of this technique. In all cases,
5
6 calculations were made based on the intensity, i.e., the intensity versus the deposited sample
7
8 amount on the needle tip. In order to mount the known amount of sample at the needle tip, 500
9
10 nL of aqueous sample solution was deposited at the needle tip using a gel loading pipette tip and
11
12 dried at room temperature. Sample could also be loaded at the tip of the needle using a
13
14 chromatography paper. In this case, a small piece of chromatography paper was first attached to
15
16 the needle tip and soaked with the sample solution and dried and then the needle with
17
18 chromatography was inserted to the solvent preloaded nanoESI capillary. This procedure
19
20 facilitates the transition of the samples trapped in the chromatography paper to the nano capillary.
21
22
23
24
25
26
27

28 10 to 5000 pg of morphine (20 ppb to 10 ppm in solution) were deposited on the needle
29
30 tip to examine the linear dynamic range of the SPA-nanoESI. Under the optimized experimental
31
32 conditions, the LOD was found to be 10 pg. Supplementary Fig. 2 (a,b) shows the mass spectra
33
34 for 10 and 5000 pg morphine. Fig. 3a shows intensity versus analyte concentration responses of
35
36 the peak at m/z 286.1431 that can be fitted to $y = 1548x - 10069$ and the R^2 value was 0.997. The
37
38 response of the signal was controlled by observing a peak from the environment and or
39
40 chromatography paper at m/z 301 which was identified using MS/MS (LTQ-XL, Thermo
41
42 Scientific, Bremen, Germany) and exact mass analysis (Orbitrap Exactive) as the sodium adduct
43
44 ion of dibutyl-phthalate, a commonly used industrial plasticizer.^{28,64} By using SPA-nanoESI
45
46 morphine could directly be detected from the raw urine after depositing the sample on the needle
47
48 tip or dipping the needle without chromatography paper about 5-10 mm into the morphine-
49
50 spiked urine solution with the lowest concentration of 1 ppm which has the similar mass
51
52 spectrum as shown in the Supplementary Fig 2(c). This limit of detection (LOD) is quite useful
53
54
55
56
57
58
59
60

1
2
3 for the analysis of real samples as the Federal Workplace Reference LOD of morphine from
4 urine is 2 ppm.⁶⁵ By sticking a small piece of chromatography paper on the needle tip during
5 sampling the LOD of morphine could be 500 ppb (500 ng/ml) or lower in raw urine.
6
7
8
9

10
11 Since, the absolute amount of the sample cannot be measured by dipping the needle to the
12 urine-spiked sample solution; we have alternatively deposited these sample solutions on the
13 needle tip and dried for the quantification purposes as mentioned previously. Under optimized
14 experimental conditions, the LOD was about 500 pg or lower for morphine spiked in urine.
15
16 Supplementary Fig. 2 (c,d) shows the mass spectra for 500 pg and 100 ng morphine in urine. Fig.
17
18 3b shows analyte amounts versus intensity responses for urine solution of morphine that can be
19 fitted to $y = 14336x + 19098$, $R^2 = 0.995$. The linearity of this technique was determined by
20 plotting a seven-point calibration curve in the range of 10-5000 pg for pure morphine and a six-
21 point calibration curve in the range of 1-100 ng for morphine-spiked urine using three replicates
22 of each concentration. The intraday precision of this method was expressed by the percentage of
23 relative standard deviation (% RSD) of the five replicate measurements. The RSD for morphine-
24 spiked (1 ng) raw urine was 17.6 %, whereas for the pure sample it was 7.0 %. We speculate that
25 a matrix effect might be the main reason behind the higher RSD value for raw urine compared to
26 the standard sample.⁵³ Morphine recovery was calculated by depositing 500 nL of urine spiked
27 morphine solution at five different concentration levels of 5 ppm, 10 ppm , 20 ppm, 50 ppm and
28 100 ppm (absolute amounts 2.5 ng, 5 ng, 10 ng, 25 ng and 50 ng) on the needle tips, and dried at
29 room temperature and six independent measurements were performed for each concentration
30 level by inserting these needles to the 2 μ L of methanolic solvent preloaded nano capillaries. We
31 note that salts from the urine cannot be dissolved in methanol completely. Therefore, the
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 clogging effect of the capillary could be eliminated during the sample measurement. An average
4
5 of 94.0 % morphine was recovered from raw urine by applying the present technique.
6
7

8 For direct analysis of tablet drugs, samples were stuck by a needle and the sample loaded
9
10 needle was inserted to a nanoESI capillary loaded with 2 μL of methanol. Supplementary Fig. 3
11
12 shows the mass spectra of tablet drugs: (a) erythromycine, (b) ciproxan, and (c) omeprazol. This
13
14 capability could be value for the real and counterfeit drugs monitoring based on their active
15
16 pharmaceutical ingredient (API)⁶⁶ in a simple and rapid manner. Additionally we have also
17
18 analyzed proteins in powder form to show the diversity of this technique. The small portion of
19
20 protein powder (~ micro gram) was picked up by the needle tip and inserted to the nanoESI
21
22 capillary in which 2 μL of methanol/water (1/1) containing 1% acetic acid was preloaded.
23
24 Supplementary Fig. 4 demonstrates the mass spectra of proteins: (a) myoglobin, (b) cytochrome
25
26 c, (c) lysozyme and (d) insulin. All the proteins are detected as major ions.
27
28
29
30
31
32

33 Matyash et al. reported that accurate profiling of lipidomes relies upon the quantitative
34
35 and unbiased recovery of the lipid species from analyzed cells, fluids, or tissues and is usually
36
37 achieved by two-phase extraction with chloroform.⁶⁷ In contrast, SPA-nanoESI does not need
38
39 such extraction procedure. Biofluid could directly be extracted by sticking the needle to the
40
41 biological tissues. The biofluid attached at the needle tip was then kept at room temperature for
42
43 three days prior to the analysis to examine the alternative storing and analyzing procedures for
44
45 thin and dried biofilm. In Fig. 4 (a) for normal kidney tissue, cholesteryl ester and
46
47 phosphatidylcholines such as $[\text{CE}(18 : 14) + \text{Na}]^+$, $[\text{PC}(34 : 2) + \text{H}]^+$, $[\text{PC}(34 : 2) + \text{Na}]^+$, $[\text{PC}(34$
48
49 $: 1) + \text{Na}]^+$, $[\text{PC}(34 : 1) + \text{K}]^+$, $[\text{PC}(36 : 2) + \text{Na}]^+$, and $[\text{PC}(38 : 4) + \text{Na}]^+$, as major components
50
51 and triacylglycerols (TAGs) such as $[\text{TAG}(52 : 2) + \text{K}]^+$ as minor ions were detected. In contrast,
52
53
54
55
56
57
58
59
60

1
2
3 in cancerous kidney tissues as shown in Fig. 4(b), triacylglycerols such as [TAG(52 : 3) + Na]⁺,
4 [TAG(52 : 2) + Na]⁺, [TAG(54 : 3) + Na]⁺, and [TAG(54 : 2) + K]⁺, and cholesteryl esters (CE)
5 such as [CE(22 : 3) + Na]⁺ as major components but negligible phosphatidylcholines such as
6 [PC(34 : 1) + H]⁺, have been detected. Namely, normal and cancerous kidney tissues are clearly
7 distinguished from dried biomaterials by the present method. Figs. 4 (c-d) show the mass spectra
8 of normal and cancerous kidney tissues without drying on the needle tip. The results obtained
9 before and after drying the biofluids are almost identical (see Figs. 4 (a-d)). As an alternative
10 approach to our previous study, selective detection of lipid and proteins³³ can be occurred by
11 changing solvents from organic to aqueous for the dried biofluids on the needle tip.
12 Supplementary Fig. 5a shows the mass spectrum of normal kidney tissues in which α and β
13 chains of hemoglobin with heme were detected with negligibly weak peaks from the PCs and
14 TAGs when methanol/water (1/1) used as solvent. In contrast, as Supplementary Fig. 5b by using
15 pure methanol different species of phosphatidylcholine and cholesteryl ester such as [CE(18 : 2)
16 + Na]⁺, [PC(34 : 1) + H]⁺, [PC(34 : 2) + H]⁺, [PC(34 : 2) + Na]⁺, [PC(34 : 1) + Na]⁺, [PC(36 : 2)
17 + Na]⁺ and [PC(36 : 1) + Na]⁺, as major components and triacylglycerols (TAGs) such as
18 [TAG(52 : 2) + Na]⁺, [TAG(52 : 2) + K]⁺ and [TAG(54 : 3) + K]⁺ minor ones were detected.
19 One drawback for this technique is the clogging of the tip which sometimes hinders the
20 performance of nanoESI. This drawback can easily be overcome by slight breaking the tip.⁶⁸
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 47 **Conclusion**

48
49
50 The SPA-nanoESI offers following fundamental properties: (a) no notable sample preparation is
51 required during the direct real world dried sample analysis, (b) powder materials can be analyzed
52 directly and (c) analysis time is really short. Since lipidomics research is of importance for in-
53
54
55
56
57
58
59
60

1
2
3 depth understanding of pathophysiological events, SPA-nanoESI might be an alternative
4
5 technique for the quick analysis of lipids from normal, and dried forensic and clinical
6
7 biomaterials. Furthermore, short analysis time and no special sample preparation make this
8
9 technique especially attractive. These capabilities are of special attention to the applications in
10
11 drug monitoring and discovery, clinical diagnostics, and omics field.
12
13
14
15
16
17

18 **Acknowledgement**

19
20
21 M.K.M. gratefully acknowledges financial support from the Japan Society for the Promotion of
22
23 Science (JSPS).
24
25
26
27
28

29 **Fig. Captions**

30
31
32 Fig. 1: Schematic showing solid probe assisted nanoESI (SPA-nanoESI) using acupuncture
33
34 needles. (a) Sampling of analytes by sticking an acupuncture needle into powder, tablet drug and
35
36 tissues with human bloods. (b) Sample picked up by an acupuncture needle is inserted into the
37
38 solvent-preloaded nanoESI capillary for electrospray.
39
40
41
42

43 Fig. 2: Mass spectrum for opium in methanol solution. The mass spectrum is an average of three
44
45 successive scans. The powder sample was touched by the needle and then the needle was
46
47 inserted to the solvent loaded nano capillary for electrospray.
48
49
50

51 Fig. 3. (a): Signal intensity responses of the protonated peak at m/z 286.1431 of morphine in
52
53 methanol by SPA-nanoESI MS: 1548x-10069, $R^2 = 0.997$, recorded from dried pure morphine in
54
55 water. (b): Signal intensity responses of the protonated peak at m/z 286.1431 of morphine in
56
57
58
59
60

1
2
3 methanol by SPA-nanoESI MS: $14336x + 19098$, $R^2 = 0.995$, recorded from dried morphine with
4
5
6 100% urine on the needle tip.
7

8
9 Fig. 4: (a,b): Positive mode SPA-nanoESI mass spectra for (a) normal and (b) cancerous kidney
10
11 tissues from biofluids dried on the needle tips. (c,d): Positive mode SPA-nanoESI mass spectra
12
13 for (c) normal and (d) cancerous kidney tissues from biofluids without drying on the needle tips
14
15 Solvent: ACN/Methanol/isopropanol (1/1/1).
16
17
18
19
20
21

22 REFERENCES

- 23
- 24
- 25
- 26 1 J. Yinon, *Mass Spectrom. Rev.*, 1991, **10**, 179–224.
- 27
- 28 2 S. Castiglioni, E. Zuccato, C. Chiabrando, R. Fanelli and R. Bagnati, *Mass Spectrom. Rev.*, 2008,
29
30 **27**, 378–394.
- 31
- 32 3 K. Schwamborn and R. M. Caprioli, *Nat. Rev. Cancer*, 2010, **10**, 639–646.
- 33
- 34 4 A. Dobos, E. Hidvégi and G. P. Somogyi, *J. Anal. Toxicol.*, 2012, **36**, 340–344.
- 35
- 36 5 H. Kataoka, H. L. Lord and J. Pawliszyn, *J. Anal. Toxicol.*, 2000, **24**, 257–265.
- 37
- 38 6 K. Hara, S. Kashimura, Y. Hieda and M. Kageura, *J. Anal. Toxicol.*, 1997, **21**, 54–58.
- 39
- 40 7 M. Concheiro, S. M. dos S. S. Simões, Ó. Quintela, A. de Castro, M. J. R. Dias, A. Cruz and M.
41
42 López-Rivadulla, *Forensic Sci. Int.*, 2007, **171**, 44–51.
- 43
- 44
- 45 8 R. G. Cooks, Z. Ouyang, Z. Takats and J. M. Wiseman, *Science*, 2006, **311**, 1566–1570.
- 46
- 47 9 M.-Z. Huang, C.-H. Yuan, S.-C. Cheng, Y.-T. Cho and J. Shiea, *Annu. Rev. Anal. Chem.*, 2010,
48
49 **3**, 43–65.
- 50
- 51
- 52 10 M. E. Monge, G. A. Harris, P. Dwivedi and F. M. Fernández, *Chem. Rev.*, 2013, **113**, 2269–2308.
- 53
- 54
- 55 11 Z. Takáts, J. M. Wiseman, B. Gologan and R. G. Cooks, *Science*, 2004, **306**, 471–473.
- 56
- 57
- 58
- 59
- 60


- 1
2
3 12 R. B. Cody, J. A. Laramée and H. D. Durst, *Anal. Chem.*, 2005, **77**, 2297–2302.
4
5
6 13 B. Hu, Y.-H. Lai, P.-K. So, H. Chen and Z.-P. Yao, *The Analyst*, 2012, **137**, 3613–3619.
7
8 14 D. R. Ifa, A. U. Jackson, G. Paglia and R. G. Cooks, *Anal. Bioanal. Chem.*, 2009, **394**, 1995–
9
10 2008.
11
12 15 A. U. Jackson, J. F. Garcia-Reyes, J. D. Harper, J. S. Wiley, A. Molina-Díaz, Z. Ouyang and R.
13
14 G. Cooks, *Analyst*, 2010, **135**, 927–933.
15
16
17 16 C. Wu, A. L. Dill, L. S. Eberlin, R. G. Cooks and D. R. Ifa, *Mass Spectrom. Rev.*, 2013, **32**, 218–
18
19 243.
20
21
22 17 J. Shiea, M.-Z. Huang, H.-J. Hsu, C.-Y. Lee, C.-H. Yuan, I. Beech and J. Sunner, *Rapid*
23
24 *Commun. Mass Spectrom. RCM*, 2005, **19**, 3701–3704.
25
26
27 18 P. Nemes and A. Vertes, *Methods Mol. Biol. Clifton NJ*, 2010, **656**, 159–171.
28
29
30 19 J. S. Sampson, A. M. Hawkridge and D. C. Muddiman, *J. Am. Soc. Mass Spectrom.*, 2006, **17**,
31
32 1712–1716.
33
34
35 20 S.-C. Cheng, T.-L. Cheng, H.-C. Chang and J. Shiea, *Anal. Chem.*, 2009, **81**, 868–874.
36
37
38 21 B. Hu, Y.-H. Lai, P.-K. So, H. Chen and Z.-P. Yao, *The Analyst*, 2012, **137**, 3613–3619.
39
40
41 22 S. L.-F. Chan, M. Y.-M. Wong, H.-W. Tang, C.-M. Che and K.-M. Ng, *Rapid Commun. Mass*
42
43 *Spectrom. RCM*, 2011, **25**, 2837–2843.
44
45
46 23 J. Liu, H. Wang, R. G. Cooks and Z. Ouyang, *Anal. Chem.*, 2011, **83**, 7608–7613.
47
48
49 24 J. Liu, R. G. Cooks and Z. Ouyang, *Anal. Chem.*, 2011, **83**, 9221–9225.
50
51
52 25 G. J. Van Berkel, A. D. Sanchez and J. M. E. Quirke, *Anal. Chem.*, 2002, **74**, 6216–6223.
53
54
55 26 V. Kertesz and G. J. Van Berkel, *J. Mass Spectrom.*, 2010, **45**, 252–260.
56
57
58 27 P. J. Roach, J. Laskin and A. Laskin, *Analyst*, 2010, **135**, 2233–2236.
59
60

- 1
2
3 28 J. Liu, H. Wang, N. E. Manicke, J.-M. Lin, R. G. Cooks and Z. Ouyang, *Anal. Chem.*, 2010, **82**,
4 2463–2471.
5
6
7
8 29 K. S. Kerian, A. K. Jarmusch and R. G. Cooks, *Analyst*, 2014, **139**, 2714–2720.
9
10 30 B. Hu, P.-K. So, H. Chen and Z.-P. Yao, *Anal. Chem.*, 2011, **83**, 8201–8207.
11
12 31 B. Hu, P.-K. So and Z.-P. Yao, *Anal. Chim. Acta*, 2014, **817**, 1–8.
13
14 32 S. Aksyonov and P. Williams, *Rapid Commun. Mass Spectrom.*, 2001, **15**, 1890–1891.
15
16 33 M. K. Mandal, K. Yoshimura, S. Saha, Z. Yu, S. Takeda and K. Hiraoka, *Anal. Chem.*, 2014, **86**,
17 987–992.
18
19
20 34 M. M. Rahman, K. Hiraoka and L. C. Chen, *Analyst*, 2013, **139**, 610–617.
21
22 35 H. Wang, P.-K. So and Z.-P. Yao, *Anal. Chim. Acta*, 2014, **809**, 109–116.
23
24 36 K. Hiraoka, L. C. Chen, T. Iwama, M. K. Mandal, S. Niinomiya, H. Suzuki, O. Ariyada, H.
25 Furuya and K. Takekawa, *J. Mass Spectrom. Soc. Jpn.*, 2010, **58**, 215–220.
26
27 37 C.-M. Hong, C.-T. Lee, Y.-M. Lee, C.-P. Kuo, C.-H. Yuan and J. Shiea, *Rapid Commun. Mass*
28 *Spectrom.*, 1999, **13**, 21–25.
29
30 38 M. K. Mandal, L. C. Chen and K. Hiraoka, *J. Am. Soc. Mass Spectrom.*, 2011, **22**, 1493–1500.
31
32 39 M. K. Mandal, L. C. Chen, Y. Hashimoto, Z. Yu and K. Hiraoka, *Anal. Methods*, 2010, **2**, 1905.
33
34 40 M. K. Mandal, L. C. Chen, Z. Yu, H. Nonami, R. Erra-Balsells and K. Hiraoka, *J. Mass*
35 *Spectrom.*, 2011, **46**, 967–975.
36
37 41 M. K. Mandal, K. Yoshimura, L. C. Chen, Z. Yu, T. Nakazawa, R. Katoh, H. Fujii, S. Takeda, H.
38 Nonami and K. Hiraoka, *J. Am. Soc. Mass Spectrom.*, 2012, **23**, 2043–2047.
39
40 42 M. K. Mandal, S. Saha, K. Yoshimura, Y. Shida, S. Takeda, H. Nonami and K. Hiraoka, *The*
41 *Analyst*, 2013, **138**, 1682–1688.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 43 K. Yoshimura, L. C. Chen, M. K. Mandal, T. Nakazawa, Z. Yu, T. Uchiyama, H. Hori, K.
4
5 Tanabe, T. Kubota, H. Fujii, R. Katoh, K. Hiraoka and S. Takeda, *J. Am. Soc. Mass Spectrom.*,
6
7 2012, **23**, 1741–1749.
8
9
10 44 K. Yoshimura, M. K. Mandal, M. Hara, H. Fujii, L. C. Chen, K. Tanabe, K. Hiraoka and S.
11
12 Takeda, *Anal. Biochem.*, 2013, **441**, 32–37.
13
14
15 45 L. C. Chen, K. Yoshimura, Z. Yu, R. Iwata, H. Ito, H. Suzuki, K. Mori, O. Ariyada, S. Takeda, T.
16
17 Kubota and K. Hiraoka, *J. Mass Spectrom.*, 2009, **44**, 1469–1477.
18
19
20 46 Z. Yu, L. C. Chen, H. Suzuki, O. Ariyada, R. Erra-Balsells, H. Nonami and K. Hiraoka, *J. Am.*
21
22 *Soc. Mass Spectrom.*, 2009, **20**, 2304–2311.
23
24
25 47 G. Petroselli, M. K. Mandal, L. C. Chen, G. T. Ruiz, E. Wolcan, K. Hiraoka, H. Nonami and R.
26
27 Erra-Balsells, *J. Mass Spectrom. JMS*, 2012, **47**, 313–321.
28
29
30 48 S. Saha, M. K. Mandal and K. Hiraoka, *Anal. Methods*, 2013, **5**, 4731–4738.
31
32
33 49 P. Liu, A. Forni and H. Chen, *Anal. Chem.*, 2014, **86**, 4024–4032.
34
35
36 50 X. Gong, Y. Zhao, S. Cai, S. Fu, C. Yang, S. Zhang and X. Zhang, *Anal. Chem.*, 2014, **86**, 3809–
37
38 3816.
39
40 51 M. K. Mandal, T. Ozawa, S. Saha, M. M. Rahman, M. Iwasa, Y. Shida, H. Nonami and K.
41
42 Hiraoka, *J. Agric. Food Chem.*, 2013, **61**, 7889–7895.
43
44 52 M. O. Rahman, M. K. Mandal, Y. Shida, S. Ninomiya, L. C. Chen, H. Nonami and K. Hiraoka, *J.*
45
46 *Mass Spectrom.*, 2013, **48**, 823–829.
47
48 53 S. Saha, L. C. Chen, M. K. Mandal and K. Hiraoka, *J. Am. Soc. Mass Spectrom.*, 2013, **24**, 341–
49
50 347.
51
52
53 54 S. Saha, M. K. Mandal, H. Nonami and K. Hiraoka, *Anal. Chim. Acta*, 2014, **839**, 1–7.
54
55
56
57
58
59
60

- 1
2
3 55 M. K. Mandal, K. Yoshimura, S. Saha, S. Ninomiya, M. O. Rahman, Z. Yu, L. C. Chen, Y.
4
5 Shida, S. Takeda, H. Nonami and K. Hiraoka, *The Analyst*, 2012, **137**, 4658–4661.
6
7
8 56 Y. Roggo, A. Edmond, P. Chalus and M. Ulmschneider, *Anal. Chim. Acta*, 2005, **535**, 79–87.
9
10 57 R. C. Schneider and K.-A. Kovar, *Forensic Sci. Int.*, 2003, **134**, 187–195.
11
12 58 N. Sondermann and Kovar K.-A., *Forensic Sci. Int.*, 1999, **106**, 147–156.
13
14 59 S. E. J. Bell, J. R. Beattie, J. J. McGarvey, K. L. Peters, N. M. S. Sirimuthu and S. J. Speers, *J.*
15
16 *Raman Spectrosc.*, 2004, **35**, 409–417.
17
18
19 60 A. B. Moreira, I. L. T. Dias, G. O. Neto, E. A. G. Zagatto and L. T. Kubota, *Anal. Chim. Acta*,
20
21 2004, **523**, 49–52.
22
23 61 A. B. Moreira, H. P. M. Oliveira, T. D. Z. Atvars, I. L. T. Dias, G. O. Neto, E. A. G. Zagatto and
24
25 L. T. Kubota, *Anal. Chim. Acta*, 2005, **539**, 257–261.
26
27
28 62 L. A. Leuthold, J.-F. Mandscheff, M. Fathi, C. Giroud, M. Augsburg, E. Varesio and G.
29
30 Hopfgartner, *Rapid Commun. Mass Spectrom. RCM*, 2006, **20**, 103–110.
31
32
33 63 R. Kikura-Hanajiri, N. Kaniwa, M. Ishibashi, Y. Makino and S. Kojima, *J. Chromatogr. B*
34
35 *Analyt. Technol. Biomed. Life. Sci.*, 2003, **789**, 139–150.
36
37
38 64 R. L. Self and W.-H. Wu, *Food Control*, 2012, **25**, 13–16.
39
40
41 65 <http://www.gpo.gov/fdsys/pkg/FR-2008-11-25/pdf/E8-26726.pdf>.
42
43
44 66 R. Kostianen, T. Kotiaho, T. Kuuranne and S. Auriola, *J. Mass Spectrom. JMS*, 2003, **38**, 357–
45
46 372.
47
48 67 V. Matyash, G. Liebisch, T. V. Kurzchalia, A. Shevchenko and D. Schwudke, *J. Lipid Res.*, 2008,
49
50 **49**, 1137–1146.
51
52
53 68 M. Wilm and M. Mann, *Anal. Chem.*, 1996, **68**, 1–8.
54
55
56
57
58
59
60

a) Direct sampling



b) Nano-electrospray




Figure 1

Fig. 1: Schematic showing solid probe assisted nanoESI (SPA-nanoESI) using acupuncture needles. (a) Sampling of analytes by sticking an acupuncture needle into powder, tablet drug and

1
2
3 tissues. (b) Sample picked up by an acupuncture needle is inserted into the solvent-preloaded
4 nanoESI capillary for electrospray.
5
6
7
8
9





Figure 2

Fig. 2: Mass spectrum for opium in methanol solution. The mass spectrum is an average of three successive scans. The powder sample was touched by the needle and then the needle was inserted to the solvent loaded nano capillary for electrospray.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(a) Calibration curve (water)



(b) Calibration curve (urine)




Figure 3

Fig. 3. (a): Signal intensity responses of the protonated peak at m/z 286.1431 of morphine in methanol by SPA-nanoESI MS: $1548x-10069$, $R^2 = 0.997$, recorded from dried pure morphine in water. (b): Signal intensity responses of the protonated peak at m/z 286.1431 of morphine in methanol by SPA-nanoESI MS: $14336x + 19098$, $R^2 = 0.995$, recorded from dried morphine with 100% urine on the needle tip.






Figure 4

Fig. 4: (a,b): Positive mode SPA-nanoESI mass spectra for (a) normal and (b) cancerous kidney tissues from biofluids dried on the needle tips. (c,d): Positive mode SPA-nanoESI mass spectra for (c) normal and (d) cancerous kidney tissues from biofluids without drying on the needle tips. Solvent: ACN/MeOH/isopropanol (1/1/1).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Powder narcotics



Tablet



Tissue with blood

b) Nano-electrospray

